The Food and Drug Administration will accept uniQure’s three-year AMT-130 data as the primary basis for an accelerated approval filing, but external controls, irreversible brain delivery and confirmatory evidence remain decisive risks.
Autonomous Medical Devices Incorporated has secured FDA clearance and a CLIA waiver for a four-virus PCR panel, but speed alone may not guarantee widespread adoption.
Moderna’s mRNA-1010 has cleared a major regulatory hurdle, but evidence in older adults, higher reactogenicity and seasonal contracting could limit its early impact.
Find out how Takeda’s oveporexton data could reshape narcolepsy type 1 care as approval, safety and access questions loom.
Find out how Belite Bio’s tinlarebant NDA could shape the first FDA treatment path for Stargardt disease type 1.
Find out how FDA alignment on ATH434 could shape Alterity Therapeutics’ pivotal Phase 3 path in multiple system atrophy.
Ebglyss gains an every-eight-week FDA maintenance option, raising new questions for atopic dermatitis biologic competition.
Find out how MAIA Biotechnology’s ateganosine trials could shape the next phase of lung cancer drug development today.
Find out how Afrezza’s pediatric FDA approval could change mealtime insulin use for children with diabetes and MannKind’s growth story.
Find out how Wockhardt’s Zaynich FDA approval could reshape Indian pharma innovation and the fight against drug-resistant infections.